 |
|
|
|
|
Product Details:
Payment & Shipping Terms:
|
| Norm: | 100mg*60 Capsules/bottle (box) | Indications:: | Leukemia, Lymphoma |
|---|---|---|---|
| Target:: | BCL-2 | Other Names: | Venetoclax/Venetoclax/Vicorelax |
| Suggestion: | Subject To Doctor's Recommendations | Save: | Seal And Store At No More Than 30°C |
| Highlight: | Leukemia 100mg 0.25g venetoclax tablet,Leukemia oral 100mg 0.25g venetoclax tablet,oral 100mg 0.25g venetoclax tablet Leukemia |
||
Venetoclax( Venclyxta)
[Drug Name]
Generic Name: Vinacrine Tablets
Trade name: VENCLEXTA
English name: Venetoclax Tablets
Hanyu Pinyin: Weinaikela Pian
[Indications
This product is used in combination with azacitidine for the treatment of newly diagnosed adult patients with acute myeloid leukemia who are not candidates for strong induction chemotherapy due to comorbidities, or who are 75 years of age and older.
[Usage and dosage]
Days 1-3 of the 1st course of treatment are dose creep.
Day 1, 100 mg
Day 2, 200 mg
Day 3, 400 mg
Day 4 and beyond, 400mg once a day for 28 days per course of treatment
On days 1-7 of each course of treatment, this product is to be used in combination with azacitidine, which is administered subcutaneously at a dose of 75 mg/m2.
[Adverse Reaction]
The most common adverse reactions (≥30%, any grade) were nausea, diarrhea, constipation, neutropenia, thrombocytopenia, hemorrhage, peripheral edema, vomiting, fatigue, febrile neutropenia, rash, and anemia.
Serious adverse reactions were reported in 75% of patients. The most common serious adverse reactions (≥5%) were febrile neutropenia, pneumonia (excluding fungal pneumonia), sepsis (excluding fungal sepsis), respiratory failure, and multiple organ dysfunction syndrome.
[Storage]
Seal and store at no more than 30°C.
Contact Person: Xing
Tel: 15235378613
